Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 5 · newest first

  1. Drug resistance and minimal residual disease in multiple myelomaCancer Drug Resistance · 2022
  2. Cancer drug resistance in multiple myelomaCancer Drug Resistance · 2022
  3. Immune checkpoint inhibitor resistance in soft tissue sarcomaCancer Drug Resistance · 2022
  4. P-glycoprotein (ABCB1) - weak dipolar interactions provide the key to understanding allocrite recognition, binding, and transportCancer Drug Resistance · 2022
  5. An overview of resistance to chemotherapy in osteosarcoma and future perspectivesCancer Drug Resistance · 2022
  6. Therapeutics to harness the immune microenvironment in multiple myelomaCancer Drug Resistance · 2022
  7. Loss of HER2 in breast cancer: biological mechanisms and technical pitfallsCancer Drug Resistance · 2022
  8. Emerging mechanisms of immunotherapy resistance in sarcomasCancer Drug Resistance · 2022
  9. Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seqCancer Drug Resistance · 2022
  10. DNA damage and metabolic mechanisms of cancer drug resistanceCancer Drug Resistance · 2022
  11. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradicationCancer Drug Resistance · 2022
  12. Venetoclax resistance: mechanistic insights and future strategiesCancer Drug Resistance · 2022
  13. Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quoCancer Drug Resistance · 2022
  14. Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?Cancer Drug Resistance · 2022
  15. Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistanceCancer Drug Resistance · 2022
  16. Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic reviewCancer Drug Resistance · 2022
  17. A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case reportCancer Drug Resistance · 2022
  18. Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approachCancer Drug Resistance · 2022
  19. Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple MyelomaCancer Drug Resistance · 2022
  20. Ovarian cancer resistance to PARPi and platinum-containing chemotherapyCancer Drug Resistance · 2022
  21. RIP140 regulates POLK gene expression and the response to alkylating drugs in colon cancer cellsCancer Drug Resistance · 2022
  22. Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancerCancer Drug Resistance · 2022
  23. Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistanceCancer Drug Resistance · 2022
  24. Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective studyCancer Drug Resistance · 2022
  25. Biological evidence of cancer stem-like cells and recurrent disease in osteosarcomaCancer Drug Resistance · 2022
  26. GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapiesCancer Drug Resistance · 2022
  27. In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivityCancer Drug Resistance · 2022
  28. Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancerCancer Drug Resistance · 2022
  29. Electrochemotherapy using thin-needle electrode improves recovery in feline nasal planum squamous cell carcinoma - a translational modelCancer Drug Resistance · 2022
  30. Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancerCancer Drug Resistance · 2022
  31. Mechanisms of chemotherapy resistance in ovarian cancerCancer Drug Resistance · 2022
  32. HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancerCancer Drug Resistance · 2022
  33. Immunotherapy resistance of lung cancerCancer Drug Resistance · 2022
  34. An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancerCancer Drug Resistance · 2022
  35. A nano-enhanced vaccine for metastatic melanoma immunotherapyCancer Drug Resistance · 2022
  36. Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancerCancer Drug Resistance · 2022
  37. Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cellsCancer Drug Resistance · 2022
  38. Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancerCancer Drug Resistance · 2022
  39. Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumoursCancer Drug Resistance · 2022
  40. Drug and apoptosis resistance in cancer stem cells (CSCs): A puzzle with many piecesCancer Drug Resistance · 2022
  41. Emerging actionable targets to treat therapy-resistant colorectal cancersCancer Drug Resistance · 2022
  42. Base excision repair accessory factors in senescence avoidance and resistance to treatmentsCancer Drug Resistance · 2022
  43. Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerCancer Drug Resistance · 2022
  44. Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancerCancer Drug Resistance · 2022
  45. Microvesicles: the functional mediators in sorafenib resistanceCancer Drug Resistance · 2022
  46. Cancer resistance to immunotherapy: What is the role of cancer stem cells?Cancer Drug Resistance · 2022
  47. Liquid biopsies in primary and secondary bone cancersCancer Drug Resistance · 2022
  48. Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancerCancer Drug Resistance · 2022
  49. Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic responseCancer Drug Resistance · 2022
  50. Improving HER2 testing reproducibility in HER2-low breast cancerCancer Drug Resistance · 2022